share_log

Analyst Scoreboard: 4 Ratings For Silence Therapeutics

Benzinga ·  Nov 16, 2024 04:01

In the preceding three months, 4 analysts have released ratings for Silence Therapeutics (NASDAQ:SLN), presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings31000
Last 30D10000
1M Ago10000
2M Ago01000
3M Ago10000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $63.5, a high estimate of $75.00, and a low estimate of $49.00. This current average has not changed from the previous average price target.

bigjpg

Investigating Analyst Ratings: An Elaborate Study

The standing of Silence Therapeutics among financial experts becomes...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment